Divis Laboratories share price has zoomed 3% and is presently trading at Rs 5,346.0.
Meanwhile, the BSE HEALTHCARE index is at 43,787.7 (up 1.0%).
Among the top gainers in the BSE HEALTHCARE index today are FDC (up 6.8%) and LAURUS LABS (up 4.0%).
NARAYANA HRUDAYALAYA (down 1.8%) and ERIS LIFESCIENCES (down 1.7%) are among the top losers today.
Over the last one year, Divis Laboratories has moved up from Rs 3,709.1 to Rs 5,346.0, registering a gain of Rs 1,637.0 (up 44.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,357.7 to 43,787.7, registering a gain of 54.4% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 135.8%), Jubilant Pharmova (up 126.1%) and GRANULES INDIA (up 119.4%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,840.0 (up 0.3%).
The top gainers among the BSE Sensex today are Bharti Airtel (up 1.5%) and Infosys (up 1.4%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 25,024.6 (up 0.4%). LTIMINDTREE and Infosys are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,880.5 to 81,840.0, registering a gain of 15,959.5 points (up 24.2%).
Divis Laboratories net profit grew 20.8% YoY to Rs 4,300 million for the quarter ended June 2024, compared to a profit of Rs 3,560 million a year ago. Net sales rose 19.1% to Rs 21,180 million during the period as against Rs 17,780 million in April-June 2023.
For the year ended March 2024, Divis Laboratories reported 12.3% decrease in net profit to Rs 16,000 million compared to net profit of Rs 18,240 million during FY23. Revenue of the company grew 1.0% to Rs 78,450 million during FY24.
The current Price to earnings ratio of Divis Laboratories, based on rolling 12 month earnings, stands at 84.8.
Equitymaster requests your view! Post a comment on "Divis Laboratories Gains 3%; BSE HEALTHCARE Index Up 1.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!